Novartis settlement
This article was originally published in The Gray Sheet
Executive Summary
Civil damages of $44.7 mil. will be paid by Novartis Nutrition to settle charges brought by the U.S. attorney's office in the Southern District of Illinois stemming from a Department of Justice investigation into marketing and pricing practices of the enteral pump industry, begun in the mid-1990s. Novartis affiliate OPI Properties' settlement includes a criminal plea and a $4.5 mil. fine. The investigation reportedly involved allegations of kickbacks in the form of discounted or free enteral pumps supplied in exchange for disposable pump set supply contracts with providers; charges for such pumps may have been passed on to Medicare and Medicaid. Competitor Abbott settled for more than $600 mil. in criminal and civil penalties in 2003 (1"The Gray Sheet" July 28, 2003, p. 7)...
You may also be interested in...
Abbott Corporate Integrity Pact Ratchets-Up Scrutiny Of Nutrition Pump Sales
Abbott's Ross Products unit will retain an independent review organization to oversee sales and marketing of enteral nutritional pumps and related disposables under a 1corporate integrity agreement between Abbott and the HHS Office of Inspector General
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.